STOCK TITAN

Endra Life Sciences Inc Stock Price, News & Analysis

NDRA Nasdaq

Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.

ENDRA Life Sciences Inc (NDRA) pioneers advanced medical imaging through its TAEUS technology and Nexus 128 system, offering non-invasive solutions for liver diagnostics and preclinical research. This page consolidates all official announcements and third-party analyses about the company’s technological advancements and strategic initiatives.

Access real-time updates on regulatory milestones, clinical trial progress, and partnerships driving innovation in photoacoustic imaging. Investors and researchers will find detailed coverage of product developments like the TAEUS liver fat quantification system and Nexus 128’s 4D scanning capabilities.

Key updates include financial results, intellectual property filings, and collaborations with global research institutions. All content is verified for accuracy and relevance to ensure informed decision-making about this emerging leader in cost-effective diagnostic imaging.

Bookmark this page to stay informed about NDRA’s progress in addressing unmet needs in NAFLD/NASH diagnosis and expanding applications of thermo-acoustic ultrasound technology across healthcare markets.

Rhea-AI Summary

ENDRA Life Sciences (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has rescheduled its second quarter conference call to August 22, 2024, at 4:30 p.m. Eastern time. The call was previously set for August 14, 2024. ENDRA will file its quarterly report on form 10-Q with the SEC as planned and issue a press release summarizing financial and operating results for Q2 2024 on the day of the call.

Participants can pre-register for the call using a provided link to receive a unique PIN for immediate access. Those unable to pre-register can dial (844) 868-8846 (U.S.) or (412) 317-5465 (International). A webcast will be available on ENDRA's Investor Relations page. A telephone replay will be accessible until August 29, 2024, and a webcast replay will be available shortly after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
conferences
-
Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced significant leadership changes. Alexander Tokman, a board member with 24+ years of global commercial leadership experience, has been appointed as acting CEO, replacing Francois Michelon. The company also added two industry veterans to key roles: Ziad Rouag as Head of Regulatory and Clinical Affairs and Richard Jacroux as Chief Financial Officer.

Tokman brings extensive experience in driving revenue growth and implementing improved strategies for startups and established companies. He aims to focus on core regulatory and commercial activities to secure approval and launch ENDRA's patented technology. Rouag's expertise in regulatory affairs will support TAEUS's domestic regulatory process, while Jacroux's financial management experience will aid in scaling the business.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.57%
Tags
management
-
Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has announced its plans to report financial results for Q2 2024 on August 14, 2024, after the U.S. financial markets close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results, provide updates on recent corporate developments, and answer questions.

Participants are encouraged to pre-register for the call using a provided link, which will grant them immediate access with a unique PIN. Those unable to pre-register can dial in using specific U.S. and International numbers. A webcast of the call will be accessible through ENDRA's Investor Relations page. Both telephone and webcast replays will be available until August 21, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary

ENDRA Life Sciences (Nasdaq: NDRA) announced the pricing of an $8.0 million public offering. The offering includes 61,538,461 shares of common stock or pre-funded warrants, each paired with Series A and B Warrants. The Series A Warrants have an exercise price of $0.22 per share, while Series B Warrants offer an alternative cashless exercise option. The closing date is expected around June 5, 2024, pending customary conditions. Net proceeds will be used for working capital and general corporate purposes. Craig-Hallum is the sole placement agent. This offering follows an SEC-approved registration statement on Form S-1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.83%
Tags
-
Rhea-AI Summary

ENDRA Life Sciences (NASDAQ: NDRA), a pioneer in Thermo Acoustic Enhanced UltraSound (TAEUS®), announced a significant update following an in-person meeting with the FDA. The meeting focused on the clinical trial design of the TAEUS liver device, which is important for ENDRA's U.S. De Novo filing. ENDRA presented a detailed description of TAEUS technology and a synopsis of their clinical study, which spans a fat fraction range representative of steatotic liver disease in the U.S.

The company provided background clinical data and statistical analyses from 45 historical study participants. The meeting highlighted ENDRA's proposed pivotal clinical study and included a demonstration of the TAEUS procedure. Key ENDRA team members, including technical staff and biostatisticians, attended the meeting. The FDA's feedback was deemed constructive, and ENDRA plans to update its clinical study protocol and statistical plan for FDA submission. This close engagement aims to ensure alignment on the pivotal study design for a future De Novo submission.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
-
Rhea-AI Summary

ENDRA Life Sciences (NASDAQ: NDRA) announced its Q1 2024 financial results, reporting a net loss of $2.8 million, or $0.26 per share, a slight improvement from a $2.9 million net loss in Q1 2023. Operating expenses decreased to $2.8 million from $2.9 million due to lower R&D costs. Cash and cash equivalents stood at $1.1 million as of March 31, 2024.

Key developments include the installation of the first TAEUS system in the UK at King’s College Hospital for clinical evaluation, aimed at assessing its liver fat measurement accuracy against MRI. The study will involve approximately 75 subjects. ENDRA is also advancing its FDA De Novo application for TAEUS, with a pre-submission meeting scheduled for Q2 2024. The company expanded its intellectual property portfolio, obtaining eight new patents in Europe and China, bringing the total to 80 issued patents globally. ENDRA is exploring licensing opportunities in non-core indications to enhance its IP portfolio value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ: NDRA) will report financial results for the first quarter of 2024 on May 14, 2024. The company will hold a conference call and webcast to discuss the results and recent corporate developments. Participants can pre-register for the call for immediate access.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.5%
Tags
conferences earnings
-
Rhea-AI Summary

ENDRA Life Sciences Inc. (NASDAQ: NDRA) has strengthened its intellectual property with the issuance of five new international patents, including three in Europe and two in China. This brings ENDRA's IP portfolio to a milestone of 80 issued patents worldwide, protecting its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents cover innovative solutions for providing RF energy to tissue, determining material types, and monitoring tissue temperature during surgical procedures, expanding the application of TAEUS technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.28%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.52%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.74%
Tags
conferences earnings

FAQ

What is the current stock price of Endra Life Sciences (NDRA)?

The current stock price of Endra Life Sciences (NDRA) is $3.16 as of May 13, 2025.

What is the market cap of Endra Life Sciences (NDRA)?

The market cap of Endra Life Sciences (NDRA) is approximately 3.6M.
Endra Life Sciences Inc

Nasdaq:NDRA

NDRA Rankings

NDRA Stock Data

3.56M
561.44k
0.14%
0.02%
5.28%
Diagnostics & Research
Electromedical & Electrotherapeutic Apparatus
Link
United States
ANN ARBOR